Gene Logic Projects $28M Loss for 2005 as it Launches $14M Drug-Repositioning Program | GenomeWeb

NEW YORK, March 17 (GenomeWeb News) - Gene Logic expects to record a loss of between $26 million and $28 million in 2005 as it invests $14 million in a new business initiative designed to help drug makers better select and reposition drug compounds, the company said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.